Statins suppress colon tumors by inhibiting KRAS condensates.

Beyond the breakthrough for RAS-driven cancers

KRAS in Colorectal Cancer: Tumorigenesis, Surgical Implications and Evolving Treatment Target

Simple Summary Mutations in the Kirsten rat sarcoma viral oncogene homologue (KRAS) play an important role in colorectal cancer and are linked to higher morbidity and mortality rates while also being historically difficult to treat. This review summarises the pathophysiology which leads the mutation to tumour formation...

SLC2A3 knockdown enhances radiosensitivity and suppresses MAPK signaling in nasopharyngeal carcinoma

Highlights • Silencing SLC2A3 reduces the malignant phenotypes of irradiated NPC cells.• SLC2A3 knockdown decreases tumorigenicity in irradiated NPC xenograft-bearing mice.• SLC2A3 knockdown enhances NPC cell radiosensitivity, partly in association with reduced MAPK pathway activation.

Post-translational modifications of KRAS: from molecular regulation to therapeutic targeting

: The rat sarcoma virus (RAS) proteins are small GTPases that regulate cell signaling and are frequently mutated in human cancers. Their activity is mainly controlled by cycling between guanosine diphosphate (GDP)-bound and guanosine triphosphate (GTP)-bound states, which is regulated by guanine nucleotide exchange fac...

Tumor growth going FAR with KRAS FARnesylation-induced phase separation.

RAS at the plasma membrane relay signals from cell-surface receptors to intracellular pathways. In Cell, Wang et al.1 show that farnesylation drives KRAS cytoplasmic condensation, contributing to its maturation. They identify statins as candidates to overcome resistance to KRAS-targeted therapies.

Calcitriol alleviates ARID2-deficient gastric cancer metastasis via inhibition of the Wnt/β-catenin signaling pathway

Highlights • ARID2 mutation promotes the metastatic capability of GC.• Disruption of ARID2-VDR interaction activates Wnt/β-catenin signaling pathway.• VDR activation prevents ARID2-deficient GC metastasis by blocking nuclear β-catenin.• Calcitriol may represent a therapeutic candidate for ARID2-deficient GC metastasis.